重编程谷氨酰胺代谢增强多发性骨髓瘤中BCMA-CAR T细胞适应性与疗效
肿瘤细胞的谷氨酰胺依赖降低局部谷氨酰胺可用性,限制抗肿瘤T细胞功能。研究以多发性骨髓瘤为模型,发现过表达谷氨酰胺转运体Asct2可增强Bcma-CAR T细胞在低谷氨酰胺下的增殖、IFN-γ产生和细胞毒活性,并延长小鼠生存;患者MM细胞高表达ASCT2预示联合免疫治疗和BCMA-CAR T细胞治疗预后不良。
要点
- 抗原特异性T细胞在谷氨酰胺受限时无法增殖或产生IFN-γ。
- Asct2过表达重编程CAR T细胞代谢适应性,增强体内持久性。
- MM细胞高表达ASCT2预示联合免疫治疗和BCMA-CAR T细胞治疗预后不良。
核心结论
- 重编程谷氨酰胺代谢可能增强多发性骨髓瘤中抗肿瘤CAR T细胞功能。
- 该方法也可能对以谷氨酰胺为主要能量来源和代谢标志的其他癌症有效。
研究设计与样本
- 研究使用多发性骨髓瘤作为谷氨酰胺依赖疾病模型。
- 在同基因和基因工程小鼠MM模型中评估Bcma-CAR T细胞。
- 在患者中分析MM细胞ASCT2表达水平与联合免疫治疗和BCMA-CAR T细胞治疗预后的关系。
主要发现
- 抗原特异性T细胞在谷氨酰胺浓度受限时无法增殖或产生IFN-γ。
- 靶向MM细胞Bcma的鼠源CAR T细胞对谷氨酰胺剥夺敏感。
- 过表达Asct2增加谷氨酰胺摄取的CAR T细胞在低谷氨酰胺浓度下增殖增强、对抗原刺激反应性增强、IFN-γ产生增加、细胞毒活性增强。
- Asct2过表达通过上调雷帕霉素机制靶点复合物1基因特征、改变溶质载体转运体谱、改善基础耗氧率和糖酵解功能重编程CAR T细胞代谢适应性,增强体内持久性。
- Asct2表达增加Bcma-CAR T细胞在同基因和基因工程小鼠MM模型中的疗效,延长小鼠生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glutamine dependence of cancer cells reduces local glutamine availability, which hinders antitumor T-cell functionality and facilitates immune evasion. We thus speculated that glutamine deprivation might be limiting efficacy of chimeric antigen receptor (CAR) T-cell therapies in patients with cancer. We have seen that antigen-specific T cells are unable to proliferate or produce interferon gamma (IFN-γ) in response to antigen stimulation when glutamine concentration is limited. Using multiple myeloma (MM) as a glutamine-dependent disease model, we found that murine CAR T cells selectively targeting B-cell maturation antigen (Bcma) in MM cells were sensitive to glutamine deprivation. However, CAR T cells engineered to increase glutamine uptake by expression of the glutamine transporter Asct2 exhibited enhanced proliferation and responsiveness to antigen stimulation, increased production of IFN-γ, and heightened cytotoxic activity, even under conditions of low glutamine concentration. Mechanistically, Asct2 overexpression reprogrammed the metabolic fitness of CAR T cells by upregulating the mechanistic target of rapamycin complex 1 gene signature, modifying the solute carrier transporter repertoire, and improving both basal oxygen consumption rate and glycolytic function, thereby enhancing CAR T-cell persistence in vivo. Accordingly, expression of Asct2 increased the efficacy of Bcma-CAR T cells in syngeneic and genetically engineered mouse models of MM, which prolonged mouse survival. In patients, higher-level expression of ASCT2 by MM cells predicted poor outcome to combined immunotherapy and BCMA-CAR T-cell therapy. Our results indicate that reprogramming glutamine metabolism may enhance antitumor CAR T-cell functionality in MM. This approach may also be effective for other cancers that depend on glutamine as a key energy source and metabolic hallmark.
引用
- Navarro F, Lozano T, Fuentes-García A, et al. Reprogramming glutamine metabolism enhances BCMA-CAR T-cell fitness and therapeutic efficacy in multiple myeloma. Blood. 2025. PMID: 40971494. doi:10.1182/blood.2024027496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。